Improve breeding efficiency
Make sure you
never miss a post.

FDA approves Zoetis products for fixed-time AI

August 07, 2013
POSTED BY: Gary Neubauer | DVM | Senior Manager | Dairy Technical Services | Zoetis

A new product approval for fixed-time artificial insemination (FTAI) improves breeding efficiency.

The Food and Drug Administration recently approved FACTREL® Injection (gonadorelin injection) for use with LUTALYSE® (dinoprost tromethamine injection) Sterile Solution to synchronize estrous cycles to allow for FTAI in lactating dairy cows.

You can learn more about the new approval in this video.

FDA approval of FACTREL Injection for use with LUTALYSE includes a flexible schedule, allowing veterinarians to customize breeding programs for their dairy clients. With flexible, approved use of Zoetis products for FTAI, veterinarians and producers now can use LUTALYSE, the most veterinarian-recommended and producer-used prostaglandin in the marketplace, on label with FACTREL in many of the synchronization protocols recommended by the Dairy Cattle Reproduction Council.1

Zoetis reproductive brands are the most researched and trusted products in the industry. With this new on-label option, dairy producers and veterinarians can continue to use those products with confidence.

Talk to your veterinarian about how to set up a reproductive program with this new on-label approval for fixed-time AI.

Important Safety Information for FACTREL INJECTION: FACTREL Injection is available through veterinary prescription only and not for use in humans. As with all drugs, FACTREL Injection should not be used in animals found to be hypersensitive to the product. See full prescribing information, here.

Important Safety Information for LUTALYSE: As with all parenteral products, aseptic technique should be used to reduce the possibility of post-injection bacterial infections. Do not administer in pregnant animals unless cessation of pregnancy is desired. Not for intravenous administration. Women of childbearing age and persons with respiratory problems should exercise extreme caution when handling this product. See full prescribing information, here.

1 MDI MAT ending June 2011.


Have a Comment? Subscribe